ArticleBreast cancer research : BCR2020

Targetable ERBB2 mutation status is an independent marker of adverse prognosis in estrogen receptor positive, ERBB2 non-amplified primary lobular breast carcinoma: a retrospective in silico analysis of public datasets.

Sasagu Kurozumi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.